Search research articles
Contact Us
Filters
Showing results (381-390 of 991) with videos related to
Page
of 100
Sort By:
Current Hypertension Reports
|
January 30, 2014
The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension
James Brian Byrd, George Bakris, Kenneth Jamerson
Nature Reviews. Nephrology
|
November 17, 2010
Epidemiology of hypertensive kidney disease
Suneel Udani, Ivana Lazich, George L Bakris
British Journal of Pharmacology
|
November 23, 2021
Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Ulrich Kintscher, George L Bakris, Peter Kolkhof
Nature Reviews. Nephrology
|
January 30, 2010
Pediatrics: blood pressure target for renoprotection in children
Robert H Mak, Joseph Flynn, George Bakris
The New England Journal of Medicine
|
March 17, 2021
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply
George L Bakris, Rajiv Agarwal, Gerasimos Filippatos, et al.
Current Diabetes Reports
|
April 20, 2022
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists
Scott Cohen, Hillel Sternlicht, George L Bakris
Cardiology Clinics
|
October 13, 2010
Pathogenesis and clinical physiology of hypertension
Mukesh Singh, George A Mensah, George Bakris
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
March 7, 2019
Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia
Shilpa Vijayakumar, Javed Butler, George L Bakris
Current Diabetes Reports
|
May 11, 2004
Management of hypertension in the cardiometabolic syndrome and diabetes
Nitin Khosla, Peter Hart, George L Bakris
Diabetes Care
|
March 22, 2018
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes
Ian H de Boer, George L Bakris
Page
of 100
Search research articles
Search
Showing results (381-390 of 991) with videos related to
Sort By:
Page
of 100
Current Hypertension Reports
|
January 30, 2014
The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension
James Brian Byrd, George Bakris, Kenneth Jamerson
Nature Reviews. Nephrology
|
November 17, 2010
Epidemiology of hypertensive kidney disease
Suneel Udani, Ivana Lazich, George L Bakris
British Journal of Pharmacology
|
November 23, 2021
Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Ulrich Kintscher, George L Bakris, Peter Kolkhof
Nature Reviews. Nephrology
|
January 30, 2010
Pediatrics: blood pressure target for renoprotection in children
Robert H Mak, Joseph Flynn, George Bakris
The New England Journal of Medicine
|
March 17, 2021
Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply
George L Bakris, Rajiv Agarwal, Gerasimos Filippatos, et al.
Current Diabetes Reports
|
April 20, 2022
Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists
Scott Cohen, Hillel Sternlicht, George L Bakris
Cardiology Clinics
|
October 13, 2010
Pathogenesis and clinical physiology of hypertension
Mukesh Singh, George A Mensah, George Bakris
European Heart Journal Supplements : Journal of the European Society of Cardiology
|
March 7, 2019
Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia
Shilpa Vijayakumar, Javed Butler, George L Bakris
Current Diabetes Reports
|
May 11, 2004
Management of hypertension in the cardiometabolic syndrome and diabetes
Nitin Khosla, Peter Hart, George L Bakris
Diabetes Care
|
March 22, 2018
Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes
Ian H de Boer, George L Bakris
Page
of 100